Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) EBITDA (2023 - 2025)

Historic EBITDA for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.4 million.

  • BioLineRx's EBITDA changed 0.0% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of -$1.4 million for FY2024, which is 0.0% changed from last year.
  • BioLineRx's EBITDA amounted to -$1.4 million in Q3 2025, which was down 0.0% from -$1.4 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's EBITDA peaked at $5.1 million during Q1 2025, and registered a low of -$12.2 million during Q1 2023.
  • Over the past 3 years, BioLineRx's median EBITDA value was -$1.4 million (recorded in 2023), while the average stood at -$1.9 million.
  • As far as peak fluctuations go, BioLineRx's EBITDA tumbled by 12507.06% in 2024, and later soared by 83663.79% in 2025.
  • BioLineRx's EBITDA (Quarter) stood at -$1.4 million in 2023, then crashed by 125.07% to -$3.2 million in 2024, then skyrocketed by 55.57% to -$1.4 million in 2025.
  • Its EBITDA stands at -$1.4 million for Q3 2025, versus -$1.4 million for Q2 2025 and $5.1 million for Q1 2025.